Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis
CONCLUSION: Estimations from this analysis indicate that those with low-intermediate RS on core biopsy are four times more likely to respond to NET than those with high-risk RS. Performing RS testing on diagnostic biopsy may be useful in guiding NET prescription.PMID:34022714 | DOI:10.1016/j.breast.2021.04.010
Source: Breast - Category: Cancer & Oncology Authors: M G Davey É J Ryan M R Boland M K Barry A J Lowery M J Kerin Source Type: research
More News: Breast Cancer | Breast Conservation Surgery | Cancer | Cancer & Oncology | Endocrine Therapy | Genetics | HER2 | Neoadjuvant Therapy | Study